The US Federal Trade Commission has finally approved Fresenius' $2bn acquisition of NxStage Medical. A complaint filed by the FTC in February 2019 claimed the deal would be anti-competitive.
The US Federal Trade Commission has approved a final order settling anti-competitive charges for Fresenius SE & Co. KGaA's proposed $2bn acquisition of NxStage Medical Inc.
Under the terms of FTC's April 9 approval order, the merged company will sell NxStage’s bloodline tubing-sets business to...
